CELCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Celcuity Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$57.12+0.54 (+0.95%)
Close on Oct 19, 2026
- Market cap
- $3.13B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
57M of 49M shares
Institutional holders
274
61 new, 60 sold out
Net institutional buying
8M
In Q2 2026
Insider trades, 12 months
0 buys · 17 sales
Net sold $327.56M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Julian C. Baker | 7,745,692 | 18.90% | 13D (active) | Aug 1, 2025 |
| Baker Bros. Advisors (GP) LLC | 4,877,963 | 9.99% | 13D (active) amendment | Jul 14, 2026 |
| Baker Bros. Advisors LP | 4,877,963 | 9.99% | 13G (passive) | Jul 14, 2026 |
| Felix J. Baker | 4,257,735 | 11.30% | 13G (passive) amendment | Mar 31, 2025 |
| Brian F. Sullivan | 4,013,203 | 9.10% | 13G (passive) amendment | Sep 30, 2025 |
| Soleus Capital Master Fund, L.P. | 3,872,184 | 9.90% | 13G (passive) amendment | Dec 31, 2024 |
| Nea 18 Vge Gp, LLC | 3,535,561 | 8.10% | 13D (active) amendment | Aug 14, 2025 |
| Bank Of America Corp /De/ | 3,170,198 | 6.50% | 13G (passive) | Jun 30, 2026 |
| Perceptive Advisors LLC | 3,160,200 | 6.80% | 13G (passive) amendment | Dec 31, 2025 |
| Avoro Capital Advisors LLC | 3,111,111 | 6.72% | 13G (passive) | Dec 31, 2025 |
| RTW Investments, LP | 3,039,621 | 6.30% | 13G (passive) | Mar 31, 2026 |
| Growth Equity Opportunities 18 VGE, LLC | 2,910,561 | 6.30% | 13D (active) amendment | Jan 14, 2026 |
| BlackRock, Inc. | 2,179,064 | 5.90% | 13G (passive) | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CELC | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 7,915,792 | 16.18% | $828.15M | – | 4.15% |
| Avoro Capital Advisors LLC | 3,400,000 | 6.95% | $355.71M | +25,000 | 3.19% |
| Rtw Investments, LP | 3,304,903 | 6.75% | $345.76M | +265,282 | 2.95% |
| Perceptive Advisors LLC | 3,197,200 | 6.53% | $334.49M | +70,000 | 5.02% |
| BlackRock, Inc. | 3,018,785 | 6.17% | $315.83M | +307,253 | 0.00% |
| State Street Corp | 1,955,304 | 4.00% | $204.56M | +436,599 | 0.01% |
| Vanguard Capital Management LLC | 1,874,137 | 3.83% | $196.07M | +91,243 | 0.00% |
| NEA Management Company, LLC | 1,710,561 | 3.50% | $178.96M | −575,000 | 11.27% |
| Soleus Capital Management, L.P. | 1,704,318 | 3.48% | $178.31M | +419,940 | 6.14% |
| Bank Of America Corp /De/ | 1,471,307 | 3.01% | $153.93M | +756,978 | 0.01% |
| Deerfield Management Company, L.P. (Series C) | 1,451,014 | 2.97% | $151.81M | −262,986 | 1.58% |
| Morgan Stanley | 1,334,545 | 2.73% | $139.62M | −11,170 | 0.01% |
| Tang Capital Management LLC | 1,314,594 | 2.69% | $137.53M | +264,594 | 6.25% |
| Toronto Dominion Bank | 1,258,758 | 2.57% | $131.69M | +376,000 | 0.15% |
| Geode Capital Management, LLC | 1,111,662 | 2.27% | $116.33M | +220,592 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 1,025,837 | 2.10% | $107.32K | −253,979 | 0.01% |
| Wellington Management Group Llp | 906,595 | 1.85% | $94.85M | +477,643 | 0.02% |
| Goldman Sachs Group Inc | 870,449 | 1.78% | $91.07M | +105,474 | 0.01% |
| Point72 Asset Management, L.P. | 650,916 | 1.33% | $68.10M | +370,592 | 0.08% |
| Hood River Capital Management LLC | 628,411 | 1.28% | $65.74M | New | 0.48% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 274 | 57M | 100.0% | 61 / 108 | 79 / 60 | 12M | 4M |
| Q1 2026 | 276 | 49M | 100.0% | 75 / 96 | 79 / 30 | 9M | 5M |
| Q4 2025 | 237 | 48M | 98.3% | 86 / 81 | 57 / 22 | 15M | 6M |
| Q3 2025 | 176 | 39M | 80.0% | 95 / 44 | 33 / 14 | 17M | 10M |
| Q2 2025 | 95 | 32M | 64.8% | 16 / 37 | 27 / 15 | 4M | 3M |
| Q1 2025 | 94 | 31M | 63.1% | 14 / 34 | 27 / 22 | 3M | 2M |
| Q4 2024 | 103 | 30M | 62.2% | 19 / 38 | 30 / 21 | 5M | 4M |
| Q3 2024 | 105 | 30M | 61.4% | 21 / 45 | 17 / 8 | 6M | 3M |
| Q2 2024 | 93 | 29M | 60.1% | 23 / 37 | 21 / 9 | 9M | 7M |
| Q1 2024 | 79 | 27M | 54.9% | 24 / 24 | 18 / 4 | 11M | 2M |
| Q4 2023 | 59 | 18M | 37.1% | 6 / 25 | 14 / 3 | 5M | 2M |
| Q3 2023 | 57 | 15M | 31.4% | 5 / 19 | 15 / 4 | 2M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CELC | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,394,056 | 2.85% | $145.85M | 0.01% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,128,339 | 2.31% | $118.05M | 1.10% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 987,675 | 2.02% | $103.33M | 0.12% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 436,212 | 0.89% | $45.64M | 0.05% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 420,597 | 0.86% | $36.33M | 0.11% | Jul 31, 2026 |
| Select Biotechnology Portfolio | 375,600 | 0.77% | $49.91M | 0.95% | May 31, 2026 |
| iShares Russell 2000 Growth ETF | 355,217 | 0.73% | $37.16M | 0.24% | Jun 30, 2026 |
| Fullerthaler Behavioral Small-Cap Growth | 350,000 | 0.72% | $36.62M | 0.59% | Jun 30, 2026 |
| Small Cap Growth Fund | 339,390 | 0.69% | $29.32M | 0.53% | Jul 31, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 289,540 | 0.59% | $30.29M | 0.31% | Jun 30, 2026 |
| Artisan International Small-Mid Fund | 286,166 | 0.58% | $29.94M | 1.18% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 270,240 | 0.55% | $28.27M | 0.19% | Jun 30, 2026 |
| Hood River Small-Cap Growth Fund | 222,657 | 0.46% | $23.29M | 0.35% | Jun 30, 2026 |
| Eventide Healthcare & Life Sciences Fund | 195,580 | 0.40% | $20.46M | 1.14% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 185,483 | 0.38% | $24.65M | 0.06% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Lance G. Laing | Chief Science Officer, Director | 1,271,000 | 2.60% | Aug 18, 2026 |
| Brian F. Sullivan | Chief Executive Officer, Director | 3,200,983 | 6.54% | Aug 18, 2026 |
| Vicky Hahne | Chief Financial Officer | 37,808 | 0.08% | Aug 18, 2026 |
| Richard E. Buller | Director | 9,319 | 0.02% | Jun 12, 2026 |
| Polly A. Murphy | Director | 6,530 | 0.01% | Jun 12, 2026 |
| Charles R. Romp | Director | 1,745 | 0.00% | Jun 9, 2026 |
| Richard Nigon | Director | 100,865 | 0.21% | Jun 9, 2026 |
| David Dalvey | Director | 66,530 | 0.14% | Jun 9, 2026 |
| Leo Furcht | Director | 12,530 | 0.03% | Jun 9, 2026 |
| Bros. Advisors Lp Baker | – | – | – | Jul 16, 2026 |
| Felix Baker | – | 7,055,748 | 14.42% | Jul 16, 2026 |
| Bros. Advisors (GP) LLC Baker | – | 703,920 | 1.44% | Jul 16, 2026 |
| Julian Baker | – | 442,940 | 0.91% | Jul 16, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Brian F. Sullivan Chief Executive Officer, Director | Aug 14, 2026 | Award | +80,000 | – | – | 1,450,199 |
| Vicky Hahne Chief Financial Officer | Aug 14, 2026 | Award | +16,000 | – | – | 37,808 |
| Lance G. Laing Chief Science Officer, Director | Aug 14, 2026 | Award | +20,000 | – | – | 1,271,000 |
| Julian Baker – | Jul 14, 2026 | Sale | −261,368 | $102.50 | $26.79M | 442,940 |
| Julian Baker – | Jul 14, 2026 | Sale | −2,838,632 | $102.50 | $290.96M | 4,372,852 |
| Leo Furcht Director | Jun 5, 2026 | Award | +1,530 | – | – | 12,530 |
| David Dalvey Director | Jun 5, 2026 | Award | +1,530 | – | – | 1,530 |
| Polly A. Murphy Director | Jun 5, 2026 | Award | +1,530 | – | – | 6,530 |
| Charles R. Romp Director | Jun 5, 2026 | Award | +1,530 | – | – | 1,745 |
| Richard E. Buller Director | Jun 5, 2026 | Award | +1,530 | – | – | 1,530 |
| Richard Nigon Director | Jun 5, 2026 | Award | +1,530 | – | – | 80,565 |
| Lance G. Laing Chief Science Officer, Director | Jun 2, 2026 | Option exercise | +1,000 | $9.89 | $9.89K | 1,251,000 |
| Richard E. Buller Director | May 19, 2026 | Gift | +1,029 | – | – | 7,789 |
| Richard E. Buller Director | May 19, 2026 | Gift | −1,029 | – | – | 0 |
| Richard E. Buller Director | May 4, 2026 | Sale(10b5-1 plan) | −365 | $143.24 | $52.28K | 6,760 |
| Richard E. Buller Director | May 4, 2026 | Option exercise | +9,000 | $5.10 | $45.90K | 15,760 |
| Richard E. Buller Director | May 4, 2026 | Sale(10b5-1 plan) | −1,289 | $137.00 | $176.59K | 14,471 |
| Richard E. Buller Director | May 4, 2026 | Sale(10b5-1 plan) | −550 | $139.00 | $76.45K | 13,921 |
| Richard E. Buller Director | May 4, 2026 | Sale(10b5-1 plan) | −1,670 | $139.58 | $233.10K | 12,251 |
| Richard E. Buller Director | May 4, 2026 | Sale(10b5-1 plan) | −2,301 | $141.03 | $324.51K | 9,950 |
| Richard E. Buller Director | May 4, 2026 | Sale(10b5-1 plan) | −2,825 | $142.04 | $401.26K | 7,125 |
| David Dalvey Director | May 4, 2026 | Sale(10b5-1 plan) | −25,000 | $140.68 | $3.52M | 65,000 |
| Richard Nigon Director | Apr 9, 2026 | Gift | −10,000 | – | – | 79,035 |
| Richard E. Buller Director | Mar 31, 2026 | Sale(10b5-1 plan) | −675 | $110.83 | $74.81K | 6,760 |
| Richard E. Buller Director | Mar 31, 2026 | Option exercise | +3,000 | $5.10 | $15.30K | 9,760 |
| Richard E. Buller Director | Mar 31, 2026 | Sale(10b5-1 plan) | −2,325 | $110.11 | $256.01K | 7,435 |
| Charles R. Romp Director | Feb 11, 2026 | Award | +215 | – | – | 215 |
| David Dalvey Director | Jan 27, 2026 | Sale(10b5-1 plan) | −20,000 | $120.03 | $2.40M | 90,000 |
| Richard Nigon Director | Dec 15, 2025 | Gift | −19,975 | – | – | 89,035 |
| Richard E. Buller Director | Dec 5, 2025 | Sale | −1,510 | $106.04 | $160.12K | 6,760 |
| Richard E. Buller Director | Dec 5, 2025 | Option exercise | +3,000 | $5.50 | $16.50K | 9,760 |
| Richard E. Buller Director | Dec 5, 2025 | Sale | −1,490 | $105.34 | $156.96K | 8,270 |
| Leo Furcht Director | Dec 4, 2025 | Option exercise | +250 | $7.60 | $1.90K | 11,000 |
| Richard E. Buller Director | Dec 2, 2025 | Gift | −500 | – | – | 6,760 |
| Richard E. Buller Director | Dec 1, 2025 | Option exercise | +1,100 | $14.83 | $16.31K | 8,360 |
| Richard E. Buller Director | Dec 1, 2025 | Sale | −1,100 | $98.13 | $107.94K | 7,260 |
| David Dalvey Director | Nov 21, 2025 | Sale(10b5-1 plan) | −15,000 | $100.00 | $1.50M | 110,000 |
| Richard E. Buller Director | Nov 20, 2025 | Sale | −3,900 | $96.73 | $377.25K | 7,260 |
| Richard E. Buller Director | Nov 20, 2025 | Option exercise | +3,900 | $14.83 | $57.84K | 11,160 |
| Richard E. Buller Director | Nov 19, 2025 | Gift | −500 | – | – | 7,260 |
| Richard Nigon Director | Sep 11, 2025 | Option exercise | +3,245 | $7.56 | $24.53K | 109,010 |
| Richard Nigon Director | Sep 11, 2025 | Option exercise | +4,672 | $7.56 | $35.32K | 105,765 |
| Bros. Advisors (GP) LLC Baker 10% owner | Sep 8, 2025 | Buy | +13,976 | $56.22 | $785.73K | 703,920 |
| Bros. Advisors (GP) LLC Baker 10% owner | Sep 8, 2025 | Buy | +151,524 | $56.22 | $8.52M | 7,207,272 |
| Bros. Advisors (GP) LLC Baker 10% owner | Sep 8, 2025 | Buy | +388 | $58.02 | $22.51K | 704,308 |
| Bros. Advisors (GP) LLC Baker 10% owner | Sep 8, 2025 | Buy | +4,212 | $58.02 | $244.38K | 7,211,484 |
| Brian F. Sullivan Chief Executive Officer, Director | Sep 2, 2025 | Option exercise | +104,340 | $8.05 | $839.94K | 1,370,199 |
| David Dalvey Director | Jul 28, 2025 | Sale(10b5-1 plan) | −4,141 | $46.05 | $190.69K | 125,000 |
| David Dalvey Director | Jul 28, 2025 | Sale(10b5-1 plan) | −16,438 | $45.29 | $744.48K | 129,141 |
| David Dalvey Director | Jul 28, 2025 | Sale(10b5-1 plan) | −22,377 | $44.36 | $992.64K | 145,579 |
| David Dalvey Director | Jul 28, 2025 | Sale(10b5-1 plan) | −57,044 | $43.30 | $2.47M | 167,956 |
| David Dalvey Director | Jul 28, 2025 | Sale(10b5-1 plan) | −2,025 | $46.05 | $93.25K | 0 |
| David Dalvey Director | Jul 28, 2025 | Sale(10b5-1 plan) | −4,163 | $45.24 | $188.33K | 2,025 |
| David Dalvey Director | Jul 28, 2025 | Sale(10b5-1 plan) | −3,137 | $44.36 | $139.16K | 6,188 |
| Richard E. Buller Director | May 27, 2025 | Gift | −1,079 | – | – | 1,029 |
| Richard E. Buller Director | May 27, 2025 | Gift | +1,079 | – | – | 7,760 |
| Richard E. Buller Director | May 19, 2025 | Award | +1,029 | – | – | 2,108 |
| Brian F. Sullivan Chief Executive Officer, Director | Apr 14, 2025 | Gift | +8,155 | – | – | 1,265,859 |
| Brian F. Sullivan Chief Executive Officer, Director | Apr 14, 2025 | Gift | −8,155 | – | – | 0 |
| Brian F. Sullivan Chief Executive Officer, Director | Mar 4, 2025 | Gift | −36,845 | – | – | 8,155 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| 667, L.P. Former Affiliate | Jul 14, 2026 | 261,368 | $26.79M | Jul 14, 2026 | Purchases of shares of common stock in the open market See Remark 2 |
| Baker Brothers Life Sciences, L.P. Former Affiliate | Jul 14, 2026 | 2,838,632 | $290.96M | Jul 14, 2026 | Purchases of shares of common stock in the open market See Remark 2 |
| David Dalvey Director | May 4, 2026 | 25,000 | $3.52M | May 4, 2026 | INVESTMENT |
| Richard E. Buller Director | May 4, 2026 | 6,000 | $842.79K | May 4, 2026 | Option Exercise |
| Richard E. Buller Director | Mar 31, 2026 | 6,000 | $661.61K | Mar 31, 2026 | Option Exercise |
| David Dalvey Director | Jan 27, 2026 | 20,000 | $2.40M | Jan 27, 2026 | INVESTMENT |
| Richard E. Buller Director | Dec 5, 2025 | 3,000 | $317.04K | Dec 5, 2025 | Option Exercise |
| Richard E. Buller Director | Dec 1, 2025 | 1,100 | $107.94K | Dec 1, 2025 | Option Exercise |
| David Dalvey Director | Nov 21, 2025 | 15,000 | $1.50M | Nov 21, 2025 | INVESTMENT |
| Richard E. Buller Director | Nov 20, 2025 | 3,900 | $377.26K | Nov 20, 2025 | Option Exercise |
| David Dalvey Director | Jul 28, 2025 | 9,325 | $420.77K | Jul 28, 2025 | STOCK GRANT |
| Venture Capital Fund LP Brightstone Director | Jul 28, 2025 | 100,000 | $4.40M | Jul 28, 2025 | INVESTMENT |
| Richard E. Buller Director | Aug 23, 2024 | 700 | $11.87K | Aug 23, 2024 | RSU |
| Richard E. Buller Director | Apr 24, 2024 | 700 | $11.95K | Apr 24, 2024 | RSU |
| Richard E. Buller Director | Dec 20, 2023 | 700 | $10.06K | Dec 20, 2023 | RSU |